Menu
Not yet recruiting NCT07243067

Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer

— Observational Renal Cell Carcinoma Clear-cell Renal Cell Carcinoma Papillary Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Proteomic profiling of urinary EVs, Blood sample collection.
Who it may be relevant to
Registry conditions: Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively collect blood specimens pre and post nephrectomy.

Interventions

  • Other Proteomic profiling of urinary EVs
    EV isolation and mass spectrometry.
  • Procedure Blood sample collection
    Blood samples collected pre- and post-nephrectomy

Primary outcome measures

  • Differentiate tumor-derived extracellular vesicle (tdEV) surface proteins expressed in benign vs malignant renal tumors [Time frame: Baseline]
  • Prediction of metastasis after surgery [Time frame: Perioperative (pre- and post-nephrectomy),]

Eligibility criteria

Inclusion criteria

  • Urine sample in existing biorepository
  • High-risk renal cell carcinoma (RCC) per American Urological Association (AUA) guidelines
  • Scheduled to undergo nephrectomy

Exclusion criteria

  • Does not meet inclusion criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

United States · 1 center
  • Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT07243067 · 25-003121 · HT9425-25-1-0607

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗